JP2012505154A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505154A5
JP2012505154A5 JP2011517819A JP2011517819A JP2012505154A5 JP 2012505154 A5 JP2012505154 A5 JP 2012505154A5 JP 2011517819 A JP2011517819 A JP 2011517819A JP 2011517819 A JP2011517819 A JP 2011517819A JP 2012505154 A5 JP2012505154 A5 JP 2012505154A5
Authority
JP
Japan
Prior art keywords
microglobulin
alpha
pharmaceutical composition
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011517819A
Other languages
English (en)
Japanese (ja)
Other versions
JP5694928B2 (ja
JP2012505154A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/005217 external-priority patent/WO2010006809A2/en
Publication of JP2012505154A publication Critical patent/JP2012505154A/ja
Publication of JP2012505154A5 publication Critical patent/JP2012505154A5/ja
Application granted granted Critical
Publication of JP5694928B2 publication Critical patent/JP5694928B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011517819A 2008-07-18 2009-07-17 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 Expired - Fee Related JP5694928B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US13533808P 2008-07-18 2008-07-18
DKPA200801024 2008-07-18
US61/135,338 2008-07-18
DKPA200801024 2008-07-18
US18938108P 2008-08-18 2008-08-18
DKPA200801116 2008-08-18
US61/189,381 2008-08-18
DKPA200801116 2008-08-18
US19750608P 2008-10-27 2008-10-27
DKPA200801478 2008-10-27
DKPA200801478 2008-10-27
US61/197,506 2008-10-27
PCT/EP2009/005217 WO2010006809A2 (en) 2008-07-18 2009-07-17 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014236500A Division JP6406987B2 (ja) 2008-07-18 2014-11-21 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用

Publications (3)

Publication Number Publication Date
JP2012505154A JP2012505154A (ja) 2012-03-01
JP2012505154A5 true JP2012505154A5 (https=) 2012-09-06
JP5694928B2 JP5694928B2 (ja) 2015-04-01

Family

ID=41550762

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011517819A Expired - Fee Related JP5694928B2 (ja) 2008-07-18 2009-07-17 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2014236500A Expired - Fee Related JP6406987B2 (ja) 2008-07-18 2014-11-21 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2015241096A Expired - Fee Related JP6175478B2 (ja) 2008-07-18 2015-12-10 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014236500A Expired - Fee Related JP6406987B2 (ja) 2008-07-18 2014-11-21 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2015241096A Expired - Fee Related JP6175478B2 (ja) 2008-07-18 2015-12-10 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用

Country Status (12)

Country Link
US (1) US10350268B2 (https=)
EP (2) EP2313106B1 (https=)
JP (3) JP5694928B2 (https=)
AU (1) AU2009270435B2 (https=)
CA (1) CA2730531A1 (https=)
DK (2) DK2638915T3 (https=)
ES (2) ES2571956T3 (https=)
HR (2) HRP20160760T1 (https=)
HU (2) HUE030274T2 (https=)
PL (2) PL2638915T3 (https=)
PT (1) PT2638915T (https=)
WO (1) WO2010006809A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1691820A4 (en) 2003-11-08 2010-03-03 Prothera Biolog PREPARATION AND COMPOSITION OF INTER ALPHA HEMMER PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE
EA022609B1 (ru) 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии
CN106928346B (zh) 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
US10226507B2 (en) * 2012-09-05 2019-03-12 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
WO2015095553A1 (en) 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
US10981963B2 (en) * 2016-03-18 2021-04-20 Guard Therapeutics International AB Alpha-1-microglobulin derived proteins and their use
CN109789193A (zh) 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
WO2018094023A2 (en) * 2016-11-16 2018-05-24 Anand Prasad Cyclic dipeptides and wound healing
EP3615937B1 (en) 2017-04-25 2026-01-28 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CN111511386A (zh) * 2017-11-03 2020-08-07 卫士医疗国际公司 α-1-微球蛋白用于保护骨髓细胞的用途
JP6906807B2 (ja) * 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置
JP2026507475A (ja) 2023-02-08 2026-03-04 ガード セラピューティクス インターナショナル エービー α－１－ミクログロブリン由来ペプチド断片及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) * 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ITMI20032528A1 (it) 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20070292421A1 (en) 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
EA022609B1 (ru) 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии

Similar Documents

Publication Publication Date Title
JP2012505154A5 (https=)
BR112022008641A2 (pt) Métodos de tratamento com modulador de miosina
HRP20161808T1 (hr) Medicinska uporaba hvatača radikala i antioksidansa alfa-1-mikroglobulin
WO2007119177A3 (en) Modified release formulations and methods of treating inflammatory bowel disease
JP2014519333A5 (https=)
SG170789A1 (en) Treatment of peripheral vascular disease using postpartum-derived cells
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
JP2011516477A5 (https=)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2018520208A5 (https=)
IN2014KN02752A (https=)
DK2099462T3 (da) Farmaceutisk præparat til behandling af inflammatoriske sygdomme i urogenitalkanalen
NZ599930A (en) Pharmaceutical compositions for the stimulation of stem cells.
EP4285990A3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
JP2009500045A5 (https=)
BRPI0720236A2 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar uma infecção bacteriana em um animal de sangue quente tal como o ser humano, e, composição farmacêutica
WO2011022633A3 (en) Method of threating cancer
WO2009054957A3 (en) Methods for diagnosis and treatment of chronic fatigue syndrome
BR112013009043B8 (pt) composto, composição farmacêutica, e, uso de um composto
JP2009507474A5 (https=)
CO6160332A2 (es) Agente para terapia y/o mejoramiento de coagulacion intravascular diseminada
WO2008121461A3 (en) Vaccine for activating helper function of cd8+ tcells